Springer Nature is making SARS-CoV-2 and COVID-19 research free View research | View latest news | Sign up for updates

Clinical Study on sustained release tablet of tripterygium Wilfordii in treating rheumatoid arthritis

  • 33 Accesses

Abstract

Adopting prospective, multi-center, random, single-blind and equal rank-control methods, 226 patients with rheumatoid arthritis (RA) were divided into two groups. The 114 patients of the test group were treated with oral sustained release tablets of Tripterygium Wilfordii (TW-SR), 2 tablets twice a day for 4 weeks, 112 patients of the control group received tablets of Tripterygium Wilfordii (TW) orally 2 tablets 3 times per day for 4 weeks. Testing results showed the total effective rates of the two groups were 92.11 % and 90.65 %, respectively (P>0.05). The adverse reaction rate of TW-SR was 20.18%, which was lower than that of TW group of 70.54% (P<0. 01). Results of pre-clinical pharmacologic experimental study demonstrated that TW-SR has obvious anti-inflammatory, analgesic and immunosuppressive actions the same as TW, while the toxicity of TW-SR was less than that of TW significantly.

This is a preview of subscription content, log in to check access.

Author information

Correspondence to Rui-Lin Li or Pei-Lin Liu or Xu-Chu Wu or Jian-Jun Wei or Li-Hua Xia.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Li, R., Liu, P., Wu, X. et al. Clinical Study on sustained release tablet of tripterygium Wilfordii in treating rheumatoid arthritis. CJIM 2, 111–114 (1996). https://doi.org/10.1007/BF02969658

Download citation

Key Words

  • rheumatoid arthritis
  • Tripterygium Wilfordii
  • sustained release tablet of Tripterygium Wilfordii